Molecular design of spacer-N-linked sialoglycopolypeptide as polymeric inhibitors against influenza virus infection

Biomacromolecules. 2009 Jul 13;10(7):1894-903. doi: 10.1021/bm900300j. Epub 2009 May 13.

Abstract

A series of spacer-N-linked glycopolymers carrying long/short α2,3/6 sialylated glycan were designed as polymeric inhibitors of influenza virus. Lactose (Lac) and N-acetyllactosamine (LN: Galβ1,4GlcNAc) were first converted to spacer-N-linked disaccharide glycosides, followed by consecutive enzymatic addition of GlcNAc and Gal residues to the glycosides. The resulting spacer-N-linked glycosides with di-, tetra-, and hexasaccharides carrying a Lac, LN, lacto-N-neotetraose (LNnT: Galβ1,4GlcNAcβ1,3Galβ1,4Glc), and LNβ1,3LNnT were coupled to the carboxy group of γ-polyglutamic acid (γ-PGA) and enzymatically converted to glycopolypeptides carrying α2,3/6 sialylated glycans. The interactions of a series of sialoglycopolypeptides with avian and human influenza virus strains were investigated using a hemagglutination inhibition assay. The avian virus A/Duck/HongKong/313/4/78 (H5N3) bound specifically, regardless of the structure of the asialo portion. In contrast, human virus A/Aichi/2/68 (H3N2) bound preferentially to long α2,6sialylated glycans with penta- or heptasaccharides in a glycan length-dependent manner. Furthermore, the Sambucus sieboldiana (SNA) lectin was also useful as a model of human virus hemagglutinin (HA) for understanding the carbohydrate binding properties, because the recognition motifs of the inner sugar in the receptor were very similar.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphainfluenzavirus / drug effects*
  • Animals
  • Drug Design
  • Ducks
  • Hemagglutination Inhibition Tests
  • Humans
  • Influenza A Virus, H3N2 Subtype
  • Influenza in Birds / drug therapy*
  • Influenza in Birds / prevention & control
  • Influenza, Human / drug therapy*
  • Influenza, Human / prevention & control*
  • Sialoglycoproteins / chemical synthesis
  • Sialoglycoproteins / pharmacology*
  • Sialoglycoproteins / therapeutic use

Substances

  • Sialoglycoproteins